Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Mantle-Cell 11Lymphoma 9Recurrence 5Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 5Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lymphatic Diseases 2Lung Neoplasms 2Leukemia 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Graft vs Host Disease 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bronchiolitis Obliterans Syndrome 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurologic Manifestations 1Metastatic Pancreatic Adenocarcinoma 1Leukemia, Lymphoid 1Leukemia, B-Cell 1

Interventions

Cyclophosphamide 42Cytarabine 25fludarabine phosphate 24Dexamethasone 23Methotrexate 22fludarabine 21Peripheral Blood Stem Cell Transplantation 21Vincristine 16Filgrastim 16venetoclax 14Etoposide 13Rituximab 12Mycophenolic Acid 12Whole-Body Irradiation 11Cyclosporine 10Clofarabine 10Calcium Dobesilate 10blinatumomab 9Tacrolimus 9pegaspargase 8Busulfan 8Bortezomib 8Alemtuzumab 8Mitoxantrone 7Melphalan 7Leucovorin 7Immunotherapy, Adoptive 7nilotinib 6Mesna 6Mercaptopurine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × ibrutinib × Clear all
NCT03960840 2026-06-04

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Novartis

Phase 1/2 Active not recruiting
217 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡